ERBB2 and breast carcinoma: Indeed, 2 clinical trials are currently assessing the efficacy of CDX‐011, a glembatumumab vedotin antibody‐drug conjugate against triple‐negative breast cancer (NCT01997333), and SYD985, a trastuzumab‐duocarmazine antibody‐drug conjugate against HER2 breast cancer (NCT03262935).